Physician profile
David M Smith
NPI 1366514382
$2,227.75
in general payments reported to CMS, 2019-2025
16 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $135 · 2021: $463 · 2022: $272 · 2023: $235 · 2024: $357 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.97 | 2019-2024 | |
| Lilly USA, LLC | $344.98 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $250.00 | 2023-2024 | Nuzyra |
| Boston Scientific Corporation | $146.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2025 | Austedo Xr |
| Genentech USA, INC. | $124.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.28 | 2024 | Airsupra |
| Abbott Laboratories | $121.35 | 2021 | |
| Amarin Pharma, INC. | $104.62 | 2019 | |
| Csl Behring | $85.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.18 | 2019-2020 | |
| Amgen INC. | $37.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.22 | 2019 | |
| Sanofi Pasteur INC. | $13.09 | 2019 | |
| Pfizer INC. | $12.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.